Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
skip to main content

Medication access information: What’s the latest?

June 21, 2022
The AAAAI with others wrote to U.S. Senate and House leadership to urge their support for additional COVID-19 relief funding that prioritizes therapeutic purchasing and research for new therapeutics for the care of millions of Americans with impaired immune systems. Read the letter.

May 25, 2022
AAAAI cites prescription access barriers causing patient harm in comments to FTC

AAAAI submitted feedback in response to a solicitation for comments by the Federal Trade Commission (FTC), which is considering whether to conduct a comprehensive study of the pharmacy benefit manager (PBM) industry. The FTC requested information about the business practices of the PBM industry and, specifically, the impact of those business practices on patients. We provided several real-world examples from our members of patients who experienced harmful delays and outright denials of medically necessary and appropriate care due to utilization management protocols. Over 24,000 comments were filed with the FTC, many of which expressed similar concerns, so we hope that our patients’ stories will help make the case to the FTC that a comprehensive study of the PBM industry is needed. Once completed, such a study could serve as the basis for legislative and regulatory reforms to reduce patient harm and reduce physician burden.

May 19, 2022
The Improving Seniors Timely Access to Care Act (H.R. 3173) surpassed 290 cosponsors in the House of Representatives. This gives the bill’s sponsors the option to file a motion to add the bill to the House Consensus Calendar—bypassing the committee process and moving it to the House floor for a vote after 25 legislative days. The legislation, endorsed by the AAAAI, seeks to reform and streamline the prior authorization process for Medicare Advantage plans. The Senate companion bill (S. 3018) has 28 bipartisan cosponsors. Earlier today, the AAAAI contacted all Senators who have not yet signed on as cosponsors to ask them to do, sharing our letter endorsing the legislation.

Follow Prescription Drug Access developments in State Legislatures and in Congress  
Review a summary of state and federal legislation specific to existing and pending step therapy, non-medical switching, accumulator adjustment program, and uniform prior authorization laws here (provided by the Coalition of State Rheumatology Organizations (CSRO) and maintained by Hart Health Strategies, expert government relations consultants to both the AAAAI and CSRO).

The AAAAI Advocacy Committee works with a drug policy specialist on the Hart Health team to help guide our advocacy and outreach efforts. Questions or concerns? Please contact advocacy@aaaai.org